Should ‘Drug Related Problems’ remain unnoticed among patients with chronic kidney disease of uncertain aetiology?

dc.contributor.authorWickramasinghe, N.D.D.
dc.contributor.authorLynch, C.B.
dc.contributor.authorCoombes, J.
dc.contributor.authorJayamanne, S.F.
dc.contributor.authorde Silva, S.T.
dc.date.accessioned2023-10-23T09:44:03Z
dc.date.available2023-10-23T09:44:03Z
dc.date.issued2023
dc.descriptionOral Presentation Abstract (OP 028), 136th Anniversary International Medical Congress, Sri Lanka Medical Association, 25th-28th July 2023, Colombo, Sri Lankaen_US
dc.description.abstractINTRODUCTION: Chronic kidney disease of uncertain aetiology (CKDu) is a major public health concern in Sri Lanka. CKDu patients often consume 10-12 drugs per day, which can result in drug-related problems (DRPs). However, emerging economies such as Sri Lanka have few safeguards in place to detect and report DRPs. OBJECTIVES: The objective of this study was to introduce clinic-based pharmacy services to detect, address and report DRPs that occurred in CKDu out-patients. METHODS: A randomized controlled clinical trial was conducted in pre-dialysis CKDu stages 4 and 5 patients at outpatient renal clinics in Teaching Hospital, Anuradhapura, Sri Lanka. DRPs were identified in both groups at baseline. The control group received usual clinic care while the intervention group received medication counseling by a clinic-based pharmacist. DRPs were identified in both groups after 12 months. RESULTS: At baseline, there were 123 and 126 patients in the control and intervention groups, respectively. 133 and 147 DRPs were identified from 80 and 79 patients in the control and intervention groups, respectively. The median number of DRPs per patient was 1 (1-2) (p=0.458) for both groups. After 12 months, there were 101 and 98 patients in the control and intervention groups, respectively. 137 and 59 DRPs were identified from 57 and 33 patients in the control and intervention groups, respectively. The median number of DRPs per patient was 2 (1-3) and 1 (1-2) (p=0.029) in control and intervention groups, respectively. CONCLUSION: A “clinic-based pharmacist” counselling is a beneficial additional service for identifying and addressing DRPs occurring in patients with CKDu.en_US
dc.identifier.citationSri Lanka Medical Association, 136th Anniversary International Medical Congress. 2023; 68 (Supplement S):S30en_US
dc.identifier.issn0009-0875
dc.identifier.urihttp://repository.kln.ac.lk/handle/123456789/26774
dc.language.isoenen_US
dc.publisherSri Lanka Medical Associationen_US
dc.subjectClinic-based pharmacisten_US
dc.subjectMedication counselingen_US
dc.subjectOut-patienten_US
dc.titleShould ‘Drug Related Problems’ remain unnoticed among patients with chronic kidney disease of uncertain aetiology?en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Abstract-book-2023-FINAL-VERSION-2.0-30.pdf
Size:
519.14 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: